dengu
import
arbovir
diseas
world
chloroquin
antimalari
agent
shown
antivir
effect
studi
evalu
effect
patient
dengu
randomis
doubleblind
studi
perform
administ
chloroquin
placebo
three
day
patient
denguerel
symptom
patient
confirm
dengu
complet
studi
total
dengu
patient
receiv
chloroquin
receiv
placebo
signific
differ
durat
diseas
degre
day
fever
howev
patient
confirm
dengu
report
substanti
decreas
pain
intens
great
improv
abil
perform
daili
activ
p
medic
symptom
return
immedi
patient
stop
take
medic
effect
observ
patient
diseas
dengu
therefor
studi
show
patient
dengu
treat
chloroquin
improv
qualiti
life
abl
resum
daili
activ
howev
chloroquin
alter
durat
diseas
intens
day
fever
studi
necessari
confirm
clinic
effect
assess
side
effect
chloroquin
dengu
patient
onlin
memoriasiocfiocruzbr
mem
inst
oswaldo
cruz
rio
de
janeiro
vol
august
dengu
import
arthropodborn
viral
infect
human
repres
import
public
health
problem
tropic
subtrop
area
world
health
organ
estim
approxim
billion
peopl
countri
risk
infect
report
million
peopl
infect
dengu
virus
denv
everi
year
individu
develop
sever
form
lead
approxim
death
annual
pinheiro
corber
dengu
result
infect
one
four
denv
serotyp
virus
belong
flavivirida
famili
transmit
human
bite
femal
aed
aegypti
mosquito
clinic
manifest
dengu
rang
mild
flulik
syndrom
occasion
associ
rash
dengu
fever
sever
form
diseas
associ
plasma
leakag
thrombocytopenia
haemorrhag
dengu
haemorrhag
fever
andor
shock
dengu
shock
syndrom
dengu
vaccin
effect
antivir
agent
avail
treatment
dengu
infect
valero
levi
nobl
et
al
mani
countri
latin
america
brazilian
popul
serious
affect
dengu
infect
inde
approxim
report
dengu
case
america
occur
brazil
one
million
case
report
five
brazilian
geograph
region
last
year
schatzmayr
chloroquin
primarili
use
antimalari
drug
due
antiinflammatori
effect
use
secondari
drug
treat
varieti
chronic
diseas
rheumatoid
arthriti
system
lupu
erythematosu
tutorureta
yebrabango
recent
sever
effort
made
identifi
effect
inexpens
univers
avail
antivir
agent
chloroquin
suggest
agent
savarino
et
al
shown
exert
antivir
effect
inhibit
replic
flavivirus
randolph
et
al
savarino
et
al
therefor
due
need
effect
treatment
dengu
base
antiinflammatori
possibl
antiflaviviru
effect
chloroquin
hypothesis
chloroquin
could
clinic
benefit
dengu
infect
set
doubleblind
randomis
studi
administ
either
chloroquin
placebo
starch
patient
suspect
dengu
diseas
patient
includ
studi
present
denguerel
symptom
fever
least
two
symptom
headach
retroorbit
pain
muscl
bone
joint
pain
nausea
vomit
rash
less
h
patient
exclud
pregnant
younger
year
old
either
cardiac
neurolog
diseas
enter
studi
patient
randomis
doubleblind
fashion
receiv
either
mg
chloroquin
mg
base
bid
identicalappear
placebo
bid
three
day
control
group
addit
use
either
chloroquin
placebo
group
similarli
treat
hydrat
symptomat
medic
analges
antipyret
drug
accord
medic
prescript
three
diagnost
test
perform
accord
welldefin
protocol
revers
transcriptionpolymeras
chain
reaction
igm
antibodi
captur
elisa
non
structur
antigen
samantigen
sampl
inni
et
al
lanciotti
et
al
dussart
et
al
castrojorg
et
al
dengu
confirm
least
two
diagnost
test
posit
patient
reevalu
one
week
later
clinic
data
associ
dengu
symptom
fever
headach
retroorbit
pain
muscl
bone
joint
pain
nausea
vomit
record
well
symptom
relat
side
effect
chloroquin
axillari
temperatur
object
measur
consid
abnorm
fever
variabl
obtain
activ
object
medic
consult
use
research
form
trial
regist
clinicaltrialsgov
studi
approv
ethic
committe
clinic
hospit
school
medicin
preto
univers
paulo
process
written
inform
consent
obtain
particip
data
present
mean
standard
deviat
number
patient
differ
two
studi
group
assess
use
unpair
test
continu
outcom
fisher
exact
test
proport
p
valu
twosid
analys
perform
use
graphpad
softwar
version
graphpad
softwar
san
diego
ca
usa
studi
conduct
midfebruari
first
week
may
one
hundr
thirtytwo
patient
assess
elig
three
meet
inclus
criteria
underw
randomis
patient
enrol
studi
adult
mean
age
year
predominantli
femal
report
mean
averag
durat
symptom
h
patient
randomis
receiv
chloroquin
randomis
receiv
placebo
seventyf
patient
febril
diseas
ofd
confirm
dengu
dengu
patient
refus
particip
complet
studi
patient
receiv
chloroquin
mean
age
year
male
durat
symptom
day
patient
receiv
placebo
mean
age
year
male
durat
symptom
day
patient
exhibit
sever
form
diseas
dengu
haemorrhag
fever
andor
shock
dengu
shock
syndrom
tabl
signific
differ
group
characterist
p
frequent
symptom
fever
bodi
ach
headach
joint
pain
retroorbit
pain
signific
differ
durat
diseas
intens
day
fever
among
dengu
patient
treat
either
chloroquin
placebo
howev
dengu
patient
report
substanti
reduct
intens
pain
great
improv
abil
perform
daili
chore
take
chloroquin
wherea
improv
report
patient
take
placebo
p
tabl
howev
find
observ
patient
ofd
includ
bacteri
pneumonia
urinari
tract
infect
influenza
diseas
includ
statist
evalu
primari
goal
studi
examin
influenc
chloroquin
evolut
dengu
diseas
interestingli
symptom
return
immedi
patient
stop
take
threeday
chloroquin
treatment
show
chloroquin
effect
like
due
antiinflammatori
action
chloroquin
rather
antivir
effect
side
effect
report
two
patient
consist
transient
blur
vision
one
loss
conscious
latter
patient
sever
dehydr
seizur
rule
base
clinic
present
followup
patient
confirm
dengu
patient
e
dengu
confirm
least
two
diagnost
test
revers
transcriptionpolymeras
chain
reaction
igm
antibodi
captur
elisa
non
structur
antigen
detect
posit
b
p
c
axillari
temperatur
consid
abnorm
fever
clinic
variabl
obtain
activ
object
medic
consult
use
research
form
e
p
sd
standard
deviat
chloroquin
alter
durat
diseas
intens
day
fever
compar
dengu
patient
take
placebo
howev
patient
take
chloroquin
report
substanti
reduct
intens
pain
great
improv
health
statu
dengu
worldwid
health
problem
affect
million
peopl
caus
innumer
death
particularli
tropic
subtrop
area
world
control
viral
vector
current
option
reduc
dengu
diseas
rate
vaccin
effect
antivir
agent
avail
treatment
dengu
infect
accordingli
import
identifi
treatment
strategi
could
reduc
burden
diseas
valero
levi
chloroquin
known
sinc
long
histori
use
antimalari
agent
altern
drug
treat
varieti
chronic
diseas
savarino
et
al
tutorureta
yebrabango
rational
use
chloroquin
dengu
patient
includ
drug
antiinflammatori
properti
possibl
antivir
effect
action
flavivirus
low
cost
univers
avail
safeti
global
public
health
import
dengu
recent
potenti
use
chloroquin
describ
viral
infect
influenza
human
immunodefici
viru
sever
acut
respiratori
syndrom
coronaviru
lanciotti
et
al
savarino
et
al
vincent
et
al
adachi
et
al
di
trani
et
al
keyaert
et
al
martinson
et
al
one
possibl
explan
antivir
effect
chloroquin
could
relat
impair
viral
replic
rais
intracellular
ph
therebi
interf
endosomemedi
viral
entri
increas
ph
acid
organel
includ
endosom
lysosom
golgi
vesicl
lead
unwant
chang
posttransl
modif
newli
synthesis
protein
particularli
inhibit
glycosyl
savarino
et
al
rolain
et
al
effect
particular
import
denv
infect
virus
requir
endosom
acidif
releas
viral
rna
cytoplasm
initi
viral
replic
lindenbach
rice
possibl
antivir
action
chloroquin
base
either
interfer
posttransl
process
viral
glycoprotein
lead
imperfect
glycosyl
undefin
interfer
late
stage
viral
replic
savarino
et
al
savarino
et
al
howev
exact
mechan
action
chloroquin
complet
elucid
differ
depend
differ
pathogen
rolain
et
al
tricou
et
al
evalu
effect
chloroquin
hospitalis
adult
patient
dengu
found
differ
viraemia
antigenaemia
durat
modest
antipyret
activ
chloroquin
intentiontotreat
popul
dengu
laboratoryconfirm
case
moreov
research
observ
trend
toward
lower
incid
dengu
haemorrhag
fever
dengu
patient
treat
chloroquin
studi
also
differ
durat
diseas
day
fever
dengu
patient
take
either
chloroquin
placebo
howev
patient
take
chloroquin
addit
routin
analges
drug
substanti
reduct
intens
pain
great
improv
health
statu
pain
amelior
observ
enrol
patient
take
chloroquin
quantifi
pain
scale
limit
studi
howev
object
inquir
evalu
denguerel
symptom
includ
pain
patient
acut
diseas
one
week
later
time
patient
return
clinic
evalu
convalesc
hypothesis
clinic
benefit
observ
dengu
patient
treat
chloroquin
could
due
drug
antiinflammatori
effect
particularli
chloroquin
tumour
necrosi
factor
tnf
inhibitor
clinic
manifest
dengu
patient
due
high
level
serum
hober
et
al
pinto
et
al
gandini
et
al
anoth
possibl
effect
chloroquin
dengu
patient
could
relat
antivir
action
lower
viral
load
thu
degre
immun
system
activ
studi
differ
therapeut
dose
differ
durat
earlier
onset
treatment
perform
evalu
vivo
effect
chloroquin
dengu
infect
moreov
would
interest
compar
effect
antiinflammatori
compound
treatment
dengu
patient
howev
nonsteroid
drug
avoid
care
patient
one
limit
studi
small
number
patient
treat
chloroquin
although
small
number
dengu
patient
includ
studi
approxim
report
improv
symptom
medic
symptom
return
immedi
patient
stop
take
medic
find
indic
chloroquin
possibl
candid
use
treatment
dengu
addit
side
effect
chloroquin
observ
studi
unremark
although
chloroquin
narrow
safeti
margin
usual
well
toler
advers
effect
headach
nausea
malais
dizzi
blur
vision
difficulti
focus
mild
gastrointestin
upset
pruritu
may
commonli
occur
sever
toxic
eg
neuromyopathi
retinopathi
bonemarrow
toxic
rare
may
occur
longterm
treatment
idiosyncrat
reaction
taylor
white
alkadi
chloroquin
may
worsen
psoriasi
though
rare
associ
seizur
psychosi
acut
toxic
frequent
found
therapeut
high
dose
administ
rapidli
parenter
rout
alkadi
toxic
effect
relat
ingest
dose
singl
dose
mgkg
consid
toxic
taylor
white
studi
safeti
dose
mg
per
day
three
day
use
adult
side
effect
unremark
furthermor
chloroquin
dosag
use
studi
similar
dosag
use
vivax
malaria
treatment
experi
side
effect
rare
treatment
howev
consid
small
number
patient
studi
necessari
evalu
safeti
chloroquin
dengu
patient
conclus
chloroquin
promot
reduct
intens
pain
improv
wellb
patient
dengu
infect
alter
durat
diseas
intens
day
fever
therefor
consid
current
option
dengu
treatment
limit
suggest
chloroquin
test
dengu
diseas
larger
number
patient
differ
chloroquin
dosag
time
administr
confirm
drug
clinic
effect
assess
side
effect
chloroquin
dengu
patient
